Attenuated response to purified protein derivative in patients with rheumatoid arthritis: study in a population with a high prevalence of tuberculosis.
about
Diagnosis and Treatment of Latent Tuberculosis Infection in Patients with Inflammatory Bowel Diseases due to Initiation of Anti-Tumor Necrosis Factor TherapyTackling tuberculosis: Insights from an international TB Summit in LondonAnalysis of predictors influencing indeterminate whole-blood interferon-gamma release assay results in patients with rheumatic diseases.Diagnosis and Treatment of Latent Tuberculosis Infection due to Initiation of Anti-TNF Therapy.QuantiFERON-TB Gold In-Tube assay for screening arthritis patients for latent tuberculosis infection before starting anti-tumor necrosis factor treatment.Significant risk and associated factors of active tuberculosis infection in Korean patients with inflammatory bowel disease using anti-TNF agents.Choice of Biologic Therapy for Patients with Rheumatoid Arthritis: The Infection Perspective.Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonistsPurified protein derivative test and its booster phenomenon in patients with rheumatoid arthritis.The Performance of Quantiferon TB Gold In-Tube as a Screening Tool in Paediatric Rheumatology prior to Initiation of Infliximab: A Single Centre's Experience.The incidence of tuberculosis in patients treated with certolizumab pegol across indications: impact of baseline skin test results, more stringent screening criteria and geographic region.Incidence of active mycobacterial infections in Brazilian patients with chronic inflammatory arthritis and negative evaluation for latent tuberculosis infection at baseline--a longitudinal analysis after using TNFa blockersHigh incidence of tuberculosis infection in rheumatic diseases and impact for chemoprophylactic prevention of tuberculosis activation during biologics therapyScreening for tuberculosis infection prior to initiation of anti-TNF therapy.Tuberculosis infection versus anti-tumor necrosis factor therapy: screening challenges in psoriatic patientsDiagnosis and treatment of latent tuberculosis infection in arthritis patients treated with tumor necrosis factor antagonists in Korea.Clinical experience of QuantiFERON(®) -TB Gold testing in patients with psoriasis treated with tumour necrosis factor blockers in Taiwan.The risk of tuberculosis in patients treated with TNF antagonists.Detection and management of latent tuberculosis infections before biologic therapy for psoriasis.The role of interferon-gamma release assays in predicting the emergence of active tuberculosis in the setting of biological treatment: a case report and review of the literature.Screening of latent tuberculosis infection by interferon-γ release assays in rheumatic patients: a systemic review and meta-analysis.Latent tuberculosis infection and tuberculosis in patients with rheumatic diseases treated with anti-tumor necrosis factor agents.Early Tuberculin Skin Test for the Diagnosis of Latent Tuberculosis Infection in Patients with Inflammatory Bowel Disease.Comparison of in vitro-specific blood tests with tuberculin skin test for diagnosis of latent tuberculosis before anti-TNF therapy.Isoniazid toxicity and TB development during biological therapy of patients with psoriasis in Colombia.Concordance between the tuberculin skin test and interferon gamma release assay (IGRA) for diagnosing latent tuberculosis infection in patients with systemic lupus erythematosus and patient characteristics associated with an indeterminate IGRA.A comparative analysis of two interferon-γ releasing assays to detect past tuberculosis infections in Japanese rheumatoid arthritis patients.Prevalence of latent tuberculosis infection in patients with moderate to severe psoriasis taking biologic therapies in a dermatologic private practice in Miami, Florida.Screening Optimization of Latent Tuberculosis Infection in Rheumatoid Arthritis Patients.A Case of Peritoneal Tuberculosis Developed after Infliximab Therapy for Refractory RA.Increased detection of latent tuberculosis by tuberculin skin test and booster phenomenon in early rheumatoid arthritis patients.Follow-up results of isoniazid chemoprophylaxis during biological therapy in Colombia.Diagnosis of latent tuberculosis infection before initiation of anti-tumor necrosis factor therapy using both tuberculin skin test and QuantiFERON-TB Gold In Tube assay.Screening for latent tuberculosis infection in psoriasis and psoriatic arthritis patients in a tuberculosis-endemic country: a comparison of the QuantiFERON®-TB Gold In-Tube test and tuberculin skin test.QuantiFERON TB Gold Test: the new standard for screening of latent tuberculosis in patients with rheumatoid arthritis?Attenuated response to purified protein derivative in patients with rheumatoid arthritis.Negative effect of immunosuppressive therapy in the performance of the QuantiFERON gold in-tube test in patients with immune-mediated inflammatory diseases.Infliximab partially impairs the anti-Mycobacterium tuberculosis immune responses of severe psoriasis patients with positive tuberculin skin-test.Evaluation of screening methods for identification of patients with chronic rheumatological disease requiring tuberculosis chemoprophylaxis prior to commencement of TNF-α antagonist therapy.Risk of tuberculosis comparison in new users of antitumour necrosis factor-α and with existing disease-modifying antirheumatic drug therapy.
P2860
Q27005716-ACC36D5B-CB4C-4E62-B88A-E3D6012623D6Q28602294-D9768CEE-C491-43B5-9F99-23680D3FA149Q33415211-5764329B-CEF2-4480-AFAF-72A2F6B7150FQ33882852-36B85198-8FDA-4728-88D4-4745D3B65589Q35154706-FCEA01F8-E1A5-4550-933F-6AB1EA6FD6FFQ35188622-F0D315ED-55D2-44F8-8AC6-D98DC9DFB5DBQ35237588-ED885875-D010-4581-B0B4-0DBBB674179EQ35605635-9BF724D3-0F9F-4234-8938-16FD7A30F908Q35615126-E279FD11-6D17-4AD0-B852-769CE87C7E65Q35687797-1AC5F6C9-2297-4C51-A4B2-6B8ED85E9C1DQ36183786-75FEF036-79F8-40C2-B98E-CA8BFC8A2011Q36321468-5DAEC9D8-8C21-46F6-880F-3110FBC37447Q36911254-4A068F26-B9B0-4E00-ADB7-CA9263DA2EFFQ36995803-C293E03E-1D22-40F6-977F-C9D4B982AFA9Q37166873-45326DE7-6052-498A-AF00-CD6AFA8EE851Q37221167-A755BB9E-74A9-4903-BA82-08729EFB36C9Q37810305-8E4B0059-CC83-49DA-A020-74FA36E76E5AQ37877262-3C9CF3AD-0B7A-456B-8F0A-5681E515DAF4Q37972320-A8415B49-E358-489F-B1D8-0A58385254B4Q38211731-A954D496-6E60-429F-8F3C-7B12D74F8238Q38265740-71FBEFA2-6FE5-4A35-8275-00B856537132Q38739251-DA198466-E8F0-4EF6-A892-24753A8CB9F8Q40282145-3068F0FC-8787-4854-BBBC-04A062FF2C22Q40680333-E589EFD9-CCAE-4996-B5BE-B3584C5A4CD8Q40745508-F8CF0D0D-2951-4B32-B55C-93BC47327EAAQ40752218-1AAE0D8A-5597-4765-81A6-CD5926E61DE8Q40793100-1C4054C3-B1C5-4EFA-BD00-5F35B6E15953Q40800468-DD66ECBA-5C1E-401E-9063-BA39CB0AC410Q41040302-C9415485-23B3-4923-B945-FA837454E811Q41372671-9106E7D6-4332-4606-93B4-5ACCF56130BFQ41429894-0CB8ECC5-3805-4B55-9C9B-B4773569D0A8Q41435919-326DFF7D-9175-438C-954B-F55878866723Q41750909-5CB7C221-E887-4674-9020-63C9BF098DABQ42205252-C61D9676-8DB4-4C83-8386-9EF54DCC77D3Q42955068-4ED61AB8-E469-47C5-9857-02DEC1948DBCQ42955854-DC580A2B-213C-4851-AB3C-5E9C51E9B73DQ45095583-56E47ADB-B5D3-42A5-ACD3-353E4F120A66Q45942161-18530B7E-8AF0-421D-B445-7CCD5D738C32Q47119702-69F27E00-EB5B-4B3D-82C2-8936000F630FQ47717769-B2FA0342-0FF6-41A9-81DC-2D059EAC768F
P2860
Attenuated response to purified protein derivative in patients with rheumatoid arthritis: study in a population with a high prevalence of tuberculosis.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Attenuated response to purifie ...... gh prevalence of tuberculosis.
@ast
Attenuated response to purifie ...... gh prevalence of tuberculosis.
@en
type
label
Attenuated response to purifie ...... gh prevalence of tuberculosis.
@ast
Attenuated response to purifie ...... gh prevalence of tuberculosis.
@en
prefLabel
Attenuated response to purifie ...... gh prevalence of tuberculosis.
@ast
Attenuated response to purifie ...... gh prevalence of tuberculosis.
@en
P2093
P356
P1476
Attenuated response to purifie ...... gh prevalence of tuberculosis.
@en
P2093
Acevedo-Vásquez E
Harrison J
Ponce de León D
Sánchez-Schwartz C
Sánchez-Torres A
P304
P356
10.1136/ARD.2004.029041
P407
P577
2005-09-01T00:00:00Z